Posted by Michael Wonder on 13 Oct 2025
Blacksmith Medicines receives FDA qualified infectious disease product and fast track designation for FG-2101, a novel antibiotic targeting LpxC
13 October 2025 - Blacksmith Medicines announced today that the US FDA has granted qualified infectious disease product and the fast track designation under the Generating Antibiotic Incentives Now (GAIN) Act for FG-2101.
This novel small molecule inhibitor of LpxC is in development for the treatment of serious infections caused by Gram negative bacteria including multi-drug-resistant strains.
